| Literature DB >> 34177760 |
Mingze Wang1,2,3,4, Yuming Jiao1,2,3,4, Chaofan Zeng1,2,3,4, Chaoqi Zhang1,2,3,4, Qiheng He1,2,3,4, Yi Yang1,2,3,4, Wenjun Tu1,2,3,4, Hancheng Qiu1,2,3,4, Huaizhang Shi5, Dong Zhang1,2,3,4, Dezhi Kang6, Shuo Wang1,2,3,4, A-Li Liu1,2,3,4,7, Weijian Jiang8, Yong Cao1,2,3,4, Jizong Zhao1,2,3,4,9.
Abstract
Aim: The aim of this guideline is to present current and comprehensive recommendations for the management of brain arteriovenous malformations (bAVMs) located in eloquent areas.Entities:
Keywords: assessment; brain arteriovenous malformation; eloquent area; guideline; treatment
Year: 2021 PMID: 34177760 PMCID: PMC8219979 DOI: 10.3389/fneur.2021.651663
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Applying classification of recommendations and level of evidence.
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Although randomized trials are unavailable, there may be clinical consensus that a particular test or therapy is useful or effective.
.
.
Definition of classes and level of evidence used in recommendations.
| Class I | Conditions for which there is evidence for and/or general agreement that the procedure or treatment is useful and effective |
| Class II | Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment |
| Class IIa | The weight of evidence or opinion is in favor of the procedure or treatment |
| Class IIb | Usefulness/efficacy is less well-established by evidence or opinion |
| Class III | Conditions for which there is evidence and/or general agreement that the procedure or treatment is not useful/effective and in some cases may be harmful |
| Therapeutic recommendations | |
| Level of evidence A | Data derived from multiple randomized clinical trials or meta-analyses |
| Level of evidence B | Data derived from a single randomized trial or non-randomized studies |
| Level of evidence C | Data derived from a single randomized trial or non-randomized studies |
| Diagnostic recommendations | |
| Level of evidence A | Data derived from multiple prospective cohort studies using a reference standard applied by a masked evaluator |
| Level of evidence B | Data derived from a single grade A study or one or more case-control studies, or studies using a reference standard applied by an unmasked evaluator |
| Level of evidence C | Consensus opinion of experts |
Figure 1PRISMA study flow diagram demonstrating the number of articles retained at each stage of data acquisition.
The details of 55 recommendations.
| A | 1 | 0 | 0 | 1 |
| B | 18 | 16 | 3 | 1 |
| C | 1 | 14 | 6 | 0 |
HDVL grading system.
| Lesion-to-eloquence | >10 mm | 1 |
| 5–10 mm | 2 | |
| <5 mm | 3 | |
| Diffuseness | Yes | 1 |
| No | 0 | |
| Deep draining veins | Yes | 1 |
| No | 0 | |
| Hemorrhagic history | Yes | 0 |
| No | 1 |
Total score = LED + Diffuseness+ Deep draining veins + Preoperative hemorrhage.
HDVL scores 1–3: operation is recommended.
HDVL scores 4–6: individualized multimodal treatment or conservative management is recommended.
Eloquent areas include: sensorimotor, speech, and visual function related brain area identified by fMRI and functional white matter fiber tracts reconstructed by DTI such as cortical spinal tract (CST), optic radiation (OR), and arcuate fasciculus (AF).
Diffuseness refers to the inclusion of normal brain tissue in the nidus.
Deep draining veins refer to part (or all) of the draining veins flow into deep veins, such as internal cerebral veins (ICV), basilar veins or precentral cerebellar veins.